5th Sep 2007 07:30
Tepnel Life Sciences PLC05 September 2007 Tepnel Life Sciences' pharmaceutical testing facility in Scotland officially opened by Scottish Enterprise 5 September 2007: Tepnel Life Sciences (AIM: TED), the international MolecularDiagnostics and Research Products and Services group, officially opened its new£4million pharmaceutical testing facility based in Livingston, Scotland, today. Scottish Enterprise CEO, Jack Perry, was present to open the state-of-the-artlaboratory, which will accommodate Tepnel's protein analysis and genomic testinglaboratories as well as the Company's existing pharmaceutical services business. Operational activity began at the Livingston facility in July this year,following a 12-month construction and validation period. The facility's 14,000sq ft first phase will be occupied by 47 staff relocatedfrom Tepnel's Edinburgh, Glasgow and Welsh operations. The second phase ofconstruction begins in September adding an additional 4000sq ft of customfit-out to house Tepnel's Molecular Services group which will providegenotyping, whole genome amplification, sequencing and gene expression services.The development of the second phase will be completed by the end of the yearand together, the two phases will house up to 20 new members of staff. Tepnel plans to establish a clinical genotyping operation at Livingston whilecontinuing its successful development of specialised products and services inhigh growth areas such as pharmacogenomics, new generations of vaccines and therapidly evolving therapeutic protein market. Tepnel's Chief Executive Officer, Ben Matzilevich, said: "We are pleased toofficially open our facility at Livingston today. We are making a substantialinvestment in the area which we hope will benefit the region by creating newemployment opportunities and encouraging further investment and industry here." Jack Perry, CEO at Scottish Enterprise said: "Scotland has a world class lifesciences sector that is further strengthened by the local commitment ofcompanies such as Tepnel Life Sciences. The company's new state-of-the-artfacility will not only support local life sciences companies, it will work toattract other global pharmaceutical companies to invest in Scotland." Tepnel's new Livingston facility was part funded by Scottish Enterprise,Edinburgh and Lothian. -Ends- For further information: Tepnel Life Sciences plc Ben Matzilevich, CEO Carol Smith Tel: 0161 946 2200 Capital MS&L Mary Clark or Catie Corcoran Tel: +44 20 7307 5330 Seymour Pierce Limited Mark Percy Tel: +44 20 7107 8000 Notes to Editors: About Tepnel Life Sciences plc Tepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services group with two divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with 195 employees. Tepnel provides test kits, reagents and services to two highly synergisticmarkets, these being Molecular Diagnostics and Biomedical Research. The company's strategy has been to identify high growth niche opportunitieswithin these multi-billion pound markets. Tepnel focuses on these opportunitieswith internally developed products, patents, expertise and know-how as well asstrategic acquisitions, to develop a leadership position within these definedmarket segments. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.L